Gastro Medical News about oxaliplatin

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Use of Antiemetic Agents in Acute Gastroenteritis

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Combination therapy with oxaliplatin and 5-fluorouracil in a patient with severe hepatic dysfunction associated with metastatic adenocarcinoma of the large bowel
Anti-Cancer Drugs, 09/11/09

Grenader T et al. – Oxaliplatin has been shown to be valuable in the treatment of patients with colorectal cancer. Many of these patients will develop liver metastases during the course of their disease, with, in some cases, severe hepatic dysfunction. The combination was well tolerated and clinical improvement continued for more than 11 months before disease progression was observed.

<< Previous
Favorable outcome of de novo hepatitis B infection after liver...

Next >>
Findings and Risk Factors of Early Mortality of Endoscopic...

Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study)
Annals of Oncology, 11/06/09 Relevance Score: 89%

Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin
Annals of Oncology, 10/19/09 Relevance Score: 87%

Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth
Expert Opinion on Investigational Drugs, 10/02/09 Relevance Score: 87%

A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors
Investigational New Drugs, 10/08/09 Relevance Score: 84%

Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer
Journal of Cancer Research & Clinical Oncology, 10/01/09 Relevance Score: 84%